The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicinePositioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network AnalysisPersonalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantationTacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft RejectionRole of pharmacogenomics in dialysis and transplantationEffects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis.Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipientsImpact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPersonalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Parsing interindividual drug variability: an emerging role for systems pharmacology.External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients.IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.Dosage individualization in children: integration of pharmacometrics in clinical practice.Calcineurin inhibitors and hypertension: a role for pharmacogenetics?Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.Genetics and nonmelanoma skin cancer in kidney transplant recipients.Use of pharmacogenomics in pediatric renal transplant recipients.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.The neurology of solid organ transplantation.Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.
P2860
Q26786582-DA8D88FB-BC94-44F4-BE5C-DD3B8F3BED43Q28082746-61F30BF8-830A-4448-ADA0-22D726DA5D12Q28468441-A83703B6-5DDB-4078-A8FC-C711F345B4ABQ28543706-CB1F4F8C-6D37-4EA2-8F91-9E29F653CC10Q33694700-37C99279-B755-471D-BC21-CCC4B72762ACQ34454797-8CF41877-9DB7-464E-805F-C57EA1E8CDBCQ35650886-CCBA8961-2131-426B-A84D-7FB0DCE79316Q35943046-AB5C98E7-2FC3-4493-8B0F-BBDE99B5467FQ35946398-BAA7A574-DC01-4941-8720-D8E1F776F428Q36183911-D7EBD06E-5DAB-402E-A8B7-5793518B0A00Q36234164-EC6FBC4F-52BF-4711-AAE0-ED4691419562Q36322918-891AB13B-6614-4F20-9333-AE0B26C59220Q36410101-3712B1A3-075A-4B5C-8720-9F61501CE60EQ36417380-95F42F9E-6F6E-43B8-99B6-5A4A91B062A1Q36806621-81CC3655-2FB4-417D-BA21-DAA96B6BA3D5Q37009025-5BD92AA1-6EA7-42BC-805B-498E3FB1464FQ37041351-8137CC1B-5F11-4D10-B587-D3051156C4B5Q37633166-59B58366-93F4-43D7-A786-AE3DAE564BC9Q37688773-424AF1D4-B04A-4CBE-9F76-17B8618D9EFFQ38240055-F9232D3A-9AA5-47A0-8549-1BA5C97E0C69Q38241677-4DFCA1AF-4F40-4AD0-936E-60F0AF410395Q38253383-38254CC8-9ABA-4387-AB1D-31504827B80DQ38330222-C268D694-848F-43FE-8F64-3BC63A31302FQ38367819-A842FD52-5F8B-4CF3-B560-D6E9C167783BQ38417581-F86B9822-2FD5-41AE-B9DF-BE9C268E72B5Q38435024-AB7BD96C-20B4-4EC2-AE64-CA8C4BB8F18CQ38501848-74E53989-7AF6-434A-9EC9-DC58FBAADED6Q38514054-6CCB958E-2E5D-4B4E-A1C5-DEF4583A28A6Q38585232-6ADB6B20-4B94-45EE-831A-52C29349D0C6Q38691788-E66DCF96-597F-44C8-8893-9574719B061BQ38748975-845CFFC9-99E4-4BFE-8EB5-F197A48341DBQ38787174-DB4EB772-E6C7-43E1-B339-67806D3A5F8AQ39041618-9CB7F4E1-7A6B-43C1-B90C-F00F896D86F7Q39675535-D31DFEFB-94F6-4694-9EBD-F9FD4869BEA5Q40322487-606888C6-2B11-4D7A-B52D-45449672FE24Q41031184-823C2CC3-FACE-42F9-8296-4765EAB1F7BEQ41107159-8A60E77F-E251-441D-B5A7-14A1E65FBE44Q41107618-C3971046-0E0E-4233-B451-F21380101DCAQ41392620-754EC9F5-8D8C-4FA9-9C4B-FC21A9929F99Q42215557-07E871B3-BD8F-4FBA-AFDA-111A48DC45C2
P2860
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of pharmacogenetics i ...... n solid organ transplantation.
@en
type
label
The role of pharmacogenetics i ...... n solid organ transplantation.
@en
prefLabel
The role of pharmacogenetics i ...... n solid organ transplantation.
@en
P2093
P2860
P1476
The role of pharmacogenetics i ...... in solid organ transplantation
@en
P2093
Dennis A Hesselink
Rachida Bouamar
Ron H N van Schaik
Teun van Gelder
P2860
P2888
P304
P356
10.1007/S40262-013-0120-3
P50
P577
2014-02-01T00:00:00Z
P5875
P6179
1020237960